primary membranous nephropathy
Conditions
Interventions
A:Prednisone acetate+rituximab
B:Tacrolimus+rituximab
C:rituximab
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? Patients who meet the diagnostic criteria for primary membranous nephropathy for initial treatment. ? Age >18 years and 3.5g)in the nephrotic range after non-immunotherapy and an estimated GFR value >45ml/(min·1.73m2)(calculated according to the CKD-EPI formula). ? Those who voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: ? Combined renal disease in addition to primary membranous nephropathy. ? Evidence of severe and irreversible renal damage (e.g., ultrasound showing a kidney <8 cm or renal biopsy with severe interstitial fibrosis, tubular atrophy, or glomerulosclerosis). ? Combined tumor, active infection, organ failure, cognitive impairment, myocardial infarction, severe arrhythmia, ALT elevation greater than 1.5 times the upper limit of normal, and severe hematopoietic disorders. ? Pregnant or lactating women or women planning to become pregnant within the next 24 months who have contraindications or allergies to the trial drug. ? Subjects who are participating in clinical trials of other drugs. ? Those who, in the investigator's opinion, are otherwise unsuitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission/ partial remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma albumin, PLA2R Ab/TSHD7A Ab levels;median time to remission, relapse rate and rate of patients with >30% decrease in eGFR at the last follow-up, side effects; | — |
Countries
China
Contacts
Public ContactGaosi Xu
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed